What is Neuronoff?
Neuronoff is at the forefront of non-pharmacological pain management, offering its innovative Injectrode® Platform. This solution is designed to provide chronic pain patients with relief through a minimally invasive, needle-based device placement. The Injectrode® bypasses the need for drugs by creating a low impedance path for electrical signals to alleviate pain, positioning Neuronoff as a key player in developing accessible and effective alternatives to repeat drug injections for chronic pain sufferers.
How much funding has Neuronoff raised?
Neuronoff has raised a total of $12.2M across 3 funding rounds:
Multiple Rounds
$12.2M
Grant (2025): $3.2M with participation from National Institutes of Health
Other Financing Round (2025): $4.5M, investors not publicly disclosed
Other Financing Round (2025): $4.5M, investors not publicly disclosed
Key Investors in Neuronoff
National Institutes of Health
The National Institutes of Health (NIH), founded in 1887 and based in Bethesda, Maryland, is an agency of the United States Department of Health and Human Services and is the primary agency of the United States government responsible for biomedical and health-related research.
What's next for Neuronoff?
The recent major strategic investment into Neuronoff signals a pivotal growth phase, likely aimed at scaling production, expanding clinical trials, and broadening market penetration. With its focus on drug-free pain relief, the company is well-positioned to capture a significant share of the burgeoning neuromodulation market. Future developments may include further platform enhancements and strategic partnerships to accelerate adoption among healthcare providers and patients seeking advanced pain management solutions.
See full Neuronoff company page
